A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides

Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) or IL-2 (WTX-124) INDUKINE™ Molecules

Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) or IL-2 (WTX-124) INDUKINE™ Molecules

Optimal Antitumor Immunity is Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 into the Tumor Microenvironment

Optimal Antitumor Immunity is Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 into the Tumor Microenvironment

Development of WTX-712, a Conditionally Active IL-21 INDUKINETM Molecule for the Treatment of Cancer

Development of WTX-712, a Conditionally Active IL-21 INDUKINETM Molecule for the Treatment of Cancer

The Combination of ACT and INDUKINE™ Therapy Leads to Improved Antitumor Immunity in Mouse Solid Tumors

The Combination of ACT and INDUKINE™ Therapy Leads to Improved Antitumor Immunity in Mouse Solid Tumors

Fully Automated Sequential Immunofluorescence (seqIF) for Hyperplex Spatial Proteomics

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas

Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytoma

Targeted removal of macrophage-secreted interleukin-1 receptor antagonist protects against lethal Candida albicans sepsis